Abstract

Invasive extravillous cytotrophoblast of the human placenta expresses galectins-1, -3, and -8 in vivo and in vitro. This study aimed to investigate the potential role of galectin-3 in cell migration and invasion, using recombinant human galectin-3 (rhgalectin-3), small molecule galectin inhibitor I47, and galectin-3 silencing. HTR-8/SVneo cell migration was stimulated by rhgalectin-3 and reduced by I47, which could be neutralised by rhgalectin-3. Inhibitor specificity and selectivity for the galectins expressed in extravillous trophoblast were validated in solid phase assays using recombinant galectin-1, -3, -8, confirming selectivity for galectin-3. HTR-8/SVneo cell migration and invasion, and invasion by isolated trophoblast cells in primary culture were significantly reduced in the presence of I47, which could be restored by rhgalectin-3. Upon HTR-8/SVneo cell treatment with galectin-3 siRNA both LGALS3 and galectin-3 protein were dramatically decreased. Silencing of galectin-3 induced significant reduction in cell migration and invasion, which was restored by rhgalectin-3. The influence on known mediators of cell invasion, MMP2 and -9, and integrins α1, α5, and β1 was followed in silenced cells, showing lower levels of MMPs and a large reduction in integrin subunit β1. These results show that galectin-3 acts as a pro-invasive autocrine/paracrine factor in trophoblast in vitro.

Details

Title
Human trophoblast requires galectin-3 for cell migration and invasion
Author
Bojić-Trbojević, Ž 1 ; Jovanović, Krivokuća M 1 ; Vilotić, A 1 ; Kolundžić, N 2 ; Stefanoska, I 1 ; Zetterberg, F 3   VIAFID ORCID Logo  ; Nilsson, U J 4   VIAFID ORCID Logo  ; Leffler, H 5   VIAFID ORCID Logo  ; Lj, Vićovac 1   VIAFID ORCID Logo 

 University of Belgrade, Banatska 31b, Laboratory for Biology of Reproduction, Institute for the Application of Nuclear Energy, Belgrade, Serbia (GRID:grid.7149.b) (ISNI:0000 0001 2166 9385) 
 University of Belgrade, Banatska 31b, Laboratory for Biology of Reproduction, Institute for the Application of Nuclear Energy, Belgrade, Serbia (GRID:grid.7149.b) (ISNI:0000 0001 2166 9385); Guy’s Hospital, London SE1 9RT, King’s College London, Faculty of Life Sciences & Medicine, Department of Women & Children’s Health, London, United Kingdom (GRID:grid.239826.4) 
 Medicinaregatan 8A, Galecto Biotech AB, Sahlgrenska Science Park, Gothenburg, Sweden (GRID:grid.7149.b) 
 Lund University, POB 124, Centre for Analysis and Synthesis, Department of Chemistry, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 BMC-C1228b, Klinikgatan 28, Section MIG, Department of Laboratory Medicine Lund University, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2180980912
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.